苏州湃芮生物科技

Suzhou Merna Therapeutics (also known as Pairui Biotech) is an innovative biotechnology company founded in 2023, specializing in the development of targeted RNA modification therapeutics. By integrating single-molecule multi-omics experiments with artificial intelligence-driven computational simulations, the company discovers novel targets and mechanisms related to RNA modification to address immune, inflammatory, and oncology diseases. Its lead program, SS-001, is a small molecule RNA m6A regulator formulated as an ointment, currently in Phase II clinical trials for the treatment of chemotherapy-induced hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR). Additionally, the company is developing PR115002, a preclinical sortilin-targeting peptide-drug conjugate (PDC) for platinum-resistant ovarian cancer.